These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 28259743)

  • 1. Cost-Effective but Bad for Health? Hepatitis C Treatment, Moral Hazard, and Opportunity Cost.
    Wong JB; Cohen JT
    Clin Gastroenterol Hepatol; 2017 Jun; 15(6):838-840. PubMed ID: 28259743
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of acute hepatitis C virus is cost-effective but at what price?
    Congly SE; Lee SS
    Hepatology; 2018 Apr; 67(4):1640-1641. PubMed ID: 29315682
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-Effective but Unaffordable and Unequal Hepatitis C Treatment in the US.
    Liu X; Shen JJ; Lee JL; Yoo JW
    Am J Gastroenterol; 2017 Nov; 112(11):1749. PubMed ID: 29109499
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Cost-Effectiveness of Hepatitis C-Positive Donor Kidney Transplantation for Hepatitis C-Negative Recipients with Concomitant Direct-Acting Antiviral Therapy.
    Goldfarb DA
    J Urol; 2019 Mar; 201(3):431. PubMed ID: 30759654
    [No Abstract]   [Full Text] [Related]  

  • 5. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
    Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R
    J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing HCV treatment - Moving beyond the cost conundrum.
    Fox DS; McCombs JS
    J Hepatol; 2016 Jul; 65(1):222-225. PubMed ID: 26876940
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals.
    Faria R; Woods B; Griffin S; Palmer S; Sculpher M; Ryder SD
    Aliment Pharmacol Ther; 2016 Oct; 44(8):866-76. PubMed ID: 27562233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting the impact of adverse events and treatment duration on medical resource utilization-related costs in hepatitis C genotype 1 treatment-naïve patients receiving antiviral therapy.
    Akpo EI; Cerri K; Kleintjens J
    Pharmacoeconomics; 2015 Apr; 33(4):409-22. PubMed ID: 25577042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical, virologic and pathologic features of asymptomatic hepatitis C virus carriers].
    Shindo M; Okuno T
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):376-80. PubMed ID: 15359825
    [No Abstract]   [Full Text] [Related]  

  • 10. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.
    Backx M; Lewszuk A; White JR; Cole J; Sreedharan A; van Sanden S; Diels J; Lawson A; Neal KR; Wiselka MJ; Ito T; Irving WL
    J Viral Hepat; 2014 Mar; 21(3):208-15. PubMed ID: 24438682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection.
    Corman S; Elbasha EH; Michalopoulos SN; Nwankwo C
    Value Health; 2017 Sep; 20(8):1110-1120. PubMed ID: 28964443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea.
    Kim DY; Han KH; Jun B; Kim TH; Park S; Ward T; Webster S; McEwan P
    PLoS One; 2017; 12(1):e0167770. PubMed ID: 28060834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C: An Eastern Perspective.
    Dan YY; Lim SG
    Gastroenterol Clin North Am; 2015 Dec; 44(4):793-805. PubMed ID: 26600220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Editorial commentary: Hepatitis C].
    Pár A
    Orv Hetil; 2015 May; 156(21):835. PubMed ID: 26038989
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
    Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
    J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No one size fits all-Shortening duration of therapy with direct-acting antivirals for hepatitis C genotype 1 infection.
    El Sherif O; Afhdal N; Curry M
    J Viral Hepat; 2017 Oct; 24(10):808-813. PubMed ID: 28581634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b.
    Liu Y; Wang Z; Tobe RG; Lin H; Wu B
    Clin Drug Investig; 2018 May; 38(5):427-437. PubMed ID: 29417464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.
    Petta S; Cabibbo G; Enea M; Macaluso FS; Plaia A; Bruno R; Gasbarrini A; Bruno S; Craxì A; Cammà C;
    Dig Liver Dis; 2014 Oct; 46(10):936-42. PubMed ID: 25066806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C Treatment Regimens Are Cost-Effective: But Compared With What?
    Mattingly TJ; Slejko JF; Mullins CD
    Ann Pharmacother; 2017 Nov; 51(11):961-969. PubMed ID: 28715911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.